7/3/2025

Triamcinolone Acetonide Injectable Suspension

Products Affected - Description

- Kenalog-40 injection, Bristol-Myers Squibb, 40 mg/mL, 1 mL vial, 1 count, NDC 00003-0293-05
- Kenalog-80 injection, Bristol-Myers Squibb, 80 mg/mL, 5 mL vial, 1 count, NDC 00003-0315-20
- Triamcinolone acetonide injection, Eugia US, 40 mg/mL, 10 mL vial, 1 count, NDC 55150-0385-01
- Triamcinolone acetonide injection, Eugia US, 40 mg/mL, 5 mL vial, 1 count, NDC 55150-0384-01
- Triamcinolone acetonide injection, Hikma, 40 mg/mL, 1 mL vial, 25 count, NDC 00143-9387-25
- Triamcinolone acetonide injection, Long Grove Pharmaceuticals, 40 mg/mL, 10 mL vial, 1 count, NDC 81298-5783-03
- Triamcinolone acetonide injection, Long Grove Pharmaceuticals, 40 mg/mL, 5 mL vial, 1 count, NDC 81298-5785-03
- Triamcinolone acetonide injection, Mylan (Viatris), 40 mg/mL, 1 mL vial, 25 count, NDC 67457-0621-99
- Triamcinolone acetonide injection, Teva, 40 mg/mL, 1 mL vial, 1 count, NDC 00703-0241-01
- Triamcinolone acetonide injection, Teva, 40 mg/mL, 10 mL vial, 1 count, NDC 00703-0245-01
- Triamcinolone acetonide injection, Teva, 40 mg/mL, 5 mL vial, 1 count, NDC 00703-0243-01

Reason for the Shortage

- Amneal has triamcinolone acetonide injectable suspension available.
- Eugia did not provide a reason for the shortage.
- Hikma did not provide a reason for the shortage.
- Long Grove has triamcinolone acetonide injectable suspension on shortage due to increased demand.
- Teva did not provide a reason for the shortage.
- Viatris did not provide a reason for the shortage.
- BMS did not provide a reason for the shortage of Kenalog injectable suspension. The company is expecting a disruption this fall.

Available Products

- Kenalog-10 injection, Bristol-Myers Squibb, 10 mg/mL, 5 mL vial, 1 count, NDC 00003-0494-20
- Kenalog-40 injection, Bristol-Myers Squibb, 40 mg/mL, 10 mL vial, 1 count, NDC 00003-0293-28
- Kenalog-40 injection, Bristol-Myers Squibb, 40 mg/mL, 5 mL vial, 1 count, NDC 00003-0293-20
- Kenalog-80 injection, Bristol-Myers Squibb, 80 mg/mL, 1 mL vial, 1 count, NDC 00003-0315-05
- Triamcinolone acetonide injection, Amneal, 40 mg/mL, 1 mL vial, 25 count, NDC 70121-1049-05
- Triamcinolone acetonide injection, Amneal, 40 mg/mL, 10 mL vial, 1 count, NDC 70121-1169-01
- Triamcinolone acetonide injection, Amneal, 40 mg/mL, 5 mL vial, 1 count, NDC 70121-1168-01
- Triamcinolone acetonide injection, Mylan (Viatris), 40 mg/mL, 10 mL vial, 25 count, NDC 67457-0623-99
- Triamcinolone acetonide injection, Mylan (Viatris), 40 mg/mL, 5 mL vial, 25 count, NDC 67457-0622-99

Estimated Resupply Dates

- BMS has Kenalog-40 1 mL vials on back order and the company cannot estimate a release date. Kenalog-80 in 5 mL vials are available in limited supply.
- Eugia has triamcinolone acetonide injectable suspension in 40 mg/mL 5 mL and 10 mL vials on intermittent back order and the company is releasing product as it becomes available.
- Hikma has triamcinolone acetonide injectable suspension in 40 mg/mL 1 mL vials on back order and the company estimates a release date in late-September to early-October 2025.
- Long Grove has triamcinolone acetonide injectable suspension in 40 mg/mL 5 mL and 10 mL vials on allocation.
- Teva has triamcinolone acetonide injectable suspension in 40 mg/mL 1 mL, 5 mL, and 10 mL vials on back order and the company cannot estimate a release date.
- Viatris has triamcinolone acetonide injectable suspension in 40 mg/mL 1 mL vials on back order and the company estimates a release date of late-July 2025.

Updated

Updated July 3, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 2, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.